Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma
Authors
Hamadani, MCollins, P
Samaniego, F
Spira, I
Davies, A
Radford, John A
Caimi, P
Menne,T
Boni, J
Cruz, H
Feingold, J
He, S
Wuerthner, J
Horwitz, M
Affiliation
Memorial Sloan Kettering Cancer Center, Basking Ridge, NJIssue Date
2018
Metadata
Show full item recordCitation
Hamadani M, Collins G, Samaniego F, Spira A, Davies A, Radford J, et al.Phase 1 study of Adct-301 (camidanlumab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-99-118198Additional Links
https://dx.doi.org/10.1182/blood-2018-99-118198Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-99-118198